Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.
Please note that adverse effects for any of our products should be reported to: Safety.AE@teva.co.il
Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here:
http://www.tevapharm.com/contact_us/
generic medicines, specialty medicines, CNS, active pharmaceutical ingredients, respiratory, biosimilars, biologics, pain care, migraine, and oncology
Teva Pharmaceutical Company | Teva Pharmaceuticals
Entity | Type | Tweets | Articles | |
---|---|---|---|---|
Life Science Leader Book and Periodical Publishing | Other 9 Dec 2024 | | ||
ALSTROM SYNDROME UK healthtech, Hospitals and Health Care | Other 30 Sep 2024 | | ||
Domain Therapeutics biotech, deeptech, Pharmaceutical Manufacturing | Other 30 Nov 2024 | | ||
e-fellows.net hrtech, Human Resources Services | Other 23 Nov 2024 | | ||
Fundación Artepaliativo it services, Wellness and Fitness Services | Other 29 Nov 2024 | | ||
AC Immune biotech, deeptech, healthtech, Biotechnology Research | Other 28 Nov 2024 | | ||
Venture Valuation AG Financial Services | Other 30 Sep 2024 | | ||
11TEN Innovation Partners Business Consulting and Services | Other 30 Sep 2024 | | ||
genOway biotech, deeptech, Biotechnology Research | Other 21 Nov 2024 | | ||
Soleterre healthtech, Civic and Social Organizations | Other 30 Sep 2024 | |